Davy James, Managing Editor

Hormones that reduce side effects may stimulate growth of cells resistant to therapy.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses developing trends in the treatment of specialty pharmacy patients.

Productivity and absenteeism improved in patients with chronic inflammatory arthritides.

Preventative measures emphasized to reduce transmission of disease.

Top stories of the week on Specialty Pharmacy Times from June 22-26.

Study finds improved screening needed for condition.

Early research in HIV and hepatitis B discontinued.

Drugs like Viagra previously thought to increase risk of malignant melanoma.

Size and speed of tumor growth similar in dogs and humans.

Court votes 6-3 in favor of upholding legislation.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group discusses how the Affordable Care Act has emphasized the importance of specialty pharmacy services.

Study finds that Medicare Part D cost saving projections are based on flawed methodology.

Small molecule agent able to detect or destroy prostate cancer cells when combined with different radionuclides.

New hepatitis C drugs moved the dream of a cure into a reality that gives patients a new chance at life.

Researchers discuss mechanism for overcoming resistance to drugs that target BRAF protein.

Increasing immune cell infiltration into tumors induces the immune system to block tumor growth.

Ron Lanton III, Esq, president of True North Political Solutions, LLC, discusses how the specialty pharmacy landscape will evolve in the coming years.

Hyperlipidemia found to alter immune response.

Top stories of the week on Specialty Pharmacy Times from June 15 to June 19.

Vitamin D may play a role in maintaining intestinal barrier.

Patients achieve drug-free remission with less expensive biologic drugs during first 2 years of treatment.

Lipid from avocados targets leukemia stem cells.

Modifying small white blood cells shows promise in treating immune disorders.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses how to evaluate the short term cost of treatment with new hepatitis C drugs versus the long term cost of care.

Necitumumab added to chemotherapy increases survival to nearly a year.

Physical aspects and quality of life issues improve with treatment.

Many patients experience distress from concerns over treatment and disease progression.

Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses how accreditation programs can enhance health care overall.

New cases have increased by nearly 50% over last 30 years.

Either patient group in need of more intensive treatment to reduce surgery risk.